PPIDT00082
Drug Information
| Name | Agalsidase beta |
|---|---|
| Sequence | LDNGLARTPTMGWLHWERFMCNLDCQEEPDSCISEKLFMEMAELMVSEGWKDAGYEYLCIDDCWMAPQRDSEGRLQADPQRFPHGIRQLANYVHSKGLKLGIYADVGNKTCAGFPGSFGYYDIDAQTFADWGVDLLKFDGCYCDSLENLADGYKHMSLALNRTGRSIVYSCEWPLYMWPFQKPNYTEIRQYCNHWRNFADIDDSWKSIKSILDWTSFNQERIVDVAGPGGWNDPDMLVIGNFGLSWNQQVTQMALWAIMAAPLFMSNDLRHISPQAKALLQDKDVIAINQDPLGKQGYQLRQGDNFEVWERPLSGLAWAVAMINRQEIGGPRSYTIAVASLGKGVACNPACFITQLLPVKRKLGFYEWTSRLRSHINPTGTVLLQLENTMQMSLKDLL |
| DrugBank_ID | DB00103 |
| Type | biotech |
| Indication | Agalsidase beta is indicated in the treatment of Fabry disease.[L16383] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection, powder, for solution | Intravenous; Parenteral |
35 MG
|
| Injection, powder, lyophilized, for solution | Intravenous |
5 mg/1mL
|
| Powder, for solution | Intravenous |
35 mg / vial
|
| Powder, for solution | Intravenous |
5 mg / vial
|
| Injection, powder, for solution | Intravenous |
35 mg
|
| Injection, powder, for solution | Intravenous |
5 mg
|
| Injection | Parenteral |
35 mg
|
| Injection, powder, lyophilized, for solution | Intravenous |
5 mg
|
| Injection, powder, lyophilized, for solution | Intravenous |
5.5 mg
|
| Injection, powder, lyophilized, for solution | Intravenous |
500000 mg
|
| Injection, powder, lyophilized, for solution | Intravenous |
|
| Injection, powder, lyophilized, for solution | Intravenous |
35 mg
|
| Injection, powder, lyophilized, for solution | Intravenous |
3500000 mg
|
| Solution | Subcutaneous |
1 mg/ml
|
| Powder | — |
35 mg/1vial
|
| Powder | — |
5 mg/1vial
|